SIN3A: A Potential Drug Target and Biomarker (G25942)

Target Name: SIN3A

NCBI ID: G25942

SIN3A

SIN3A: A Potential Drug Target and Biomarker

Sin3a, a protein encoded by the gene SIN3A, is a key regulator of the cell cycle and has been implicated in various cellular processes. The SIN3A gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these processes has led to its potential as a drug target or biomarker.

Sin3a functions as a critical regulator of the cell cycle, specifically the G1/S transition. During the G1 phase, Sin3a promotes the accumulation of chromatin in the center of the cell, while during the S phase, it facilitates the dissociation of chromatin from the nuclear envelope and allows for the movement of chromosomes to the opposite side of the cell. This regulation is crucial for the proper functioning of the cell and is often disrupted in various diseases.

Sin3a has also been shown to play a role in the regulation of cell apoptosis, a process that is essential for the regulation of cell growth and maintenance. When cells are no longer able to divide or have served their purpose, they undergo apoptosis, a process that is often associated with disease. Sin3a has been shown to regulate the apoptosis-associated protein (AP-120) and to play a role in the regulation of DNA double-strand break repair.

In addition to its role in cell regulation, Sin3a has also been shown to be involved in various signaling pathways. It has been shown to be a positive regulator of the T-cell receptor (TCR) signaling pathway and has been implicated in the regulation of immune cell function.

Sin3a has also been shown to be involved in the regulation of cellular migration. It has been shown to promote the migration of cancer cells to new tumors and has been implicated in the development of neurodegenerative diseases.

Sin3a has also been shown to play a role in the regulation of inflammation. It has been shown to promote the production of pro-inflammatory cytokines and to contribute to the development of autoimmune disorders.

Sin3a has also been implicated in the regulation of aging and age-related diseases. It has been shown to promote the accumulation of age-related mutations in the DNA and to contribute to the development of age-related diseases.

In conclusion, Sin3a is a protein that has been shown to play a critical role in the regulation of various cellular processes and has been implicated in the development and progression of various diseases. Its potential as a drug target or biomarker makes it an attractive target for future research. Further studies are needed to fully understand the role of Sin3a in these processes and to develop effective therapies based on its properties.

Protein Name: SIN3 Transcription Regulator Family Member A

Functions: Acts as a transcriptional repressor. Corepressor for REST. Interacts with MXI1 to repress MYC responsive genes and antagonize MYC oncogenic activities. Also interacts with MXD1-MAX heterodimers to repress transcription by tethering SIN3A to DNA. Acts cooperatively with OGT to repress transcription in parallel with histone deacetylation. Involved in the control of the circadian rhythms. Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex through histone deacetylation. Cooperates with FOXK1 to regulate cell cycle progression probably by repressing cell cycle inhibitor genes expression (By similarity). Required for cortical neuron differentiation and callosal axon elongation (By similarity)

The "SIN3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIN3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets